Jonathan Trent, MD, PhD, University of Miami, Miami, FL, outlines how the triggering of the tumor phenotype of soft tissue sarcomas (STSs) by distinct molecular or genetic events, is being taken advantage of in therapeutic development. Translocation events frequently lead to the expression of distinct transcription factors and kinases which vary between and within tumor types. Robust therapies targeting kinases continue to be developed, of which Dr. Trent gives numerous examples. However, the investigation of therapies for transcription factor-driven sarcomas is proving more challenging, as is the search for effective treatments for those subsets with multiple genetic mutations. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
